EP1435776A4
(de)
|
2001-09-24 |
2006-01-25 |
Univ Pittsburgh |
Impfstoff gegen krebs sowie diagnoseverfahren und -reagenzien
|
CA2566363C
(en)
|
2004-05-19 |
2014-12-16 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
WO2006014570A2
(en)
|
2004-07-06 |
2006-02-09 |
3D Matrix, Inc. |
Purified amphilic peptide compositions and uses thereof
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
DE602006003695D1
(de)
|
2005-01-05 |
2009-01-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
GB0511124D0
(en)
*
|
2005-06-01 |
2005-07-06 |
Avidex Ltd |
High affinity melan-a t cell receptors
|
US8883507B2
(en)
|
2005-10-18 |
2014-11-11 |
The Regents Of The University Of Colorado |
Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
|
EP1969005A1
(de)
*
|
2005-12-20 |
2008-09-17 |
Erasmus University Medical Center Rotterdam |
Apoptoseinduzierende proteinkomplexe und deren therapeutische verwendung
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
WO2008037943A1
(en)
*
|
2006-09-29 |
2008-04-03 |
Medigene Limited |
Cells transformed with nucleic acid encoding ny-eso t cell receptors
|
WO2008038002A2
(en)
*
|
2006-09-29 |
2008-04-03 |
Medigene Limited |
T cell therapies
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
CA2700278A1
(en)
*
|
2007-09-25 |
2009-04-02 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
KR101803099B1
(ko)
|
2008-05-16 |
2017-11-30 |
타이가 바이오테크놀로지스, 인코포레이티드 |
항체 및 그 제조 방법
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
JP5812861B2
(ja)
|
2008-08-28 |
2015-11-17 |
タイガ バイオテクノロジーズ,インク. |
Mycの修飾物質、該mycの修飾物質を使用する方法、およびmycを調節する薬剤を同定する方法
|
GB0816096D0
(en)
*
|
2008-09-04 |
2008-10-15 |
Medigene Ltd |
Diabetes t cell receptors
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
AU2010358291A1
(en)
*
|
2010-07-28 |
2013-02-28 |
Immunocore Ltd |
T cell receptors
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
WO2013041865A1
(en)
*
|
2011-09-22 |
2013-03-28 |
Immunocore Limited |
T cell receptors
|
EP2760892A1
(de)
|
2011-09-29 |
2014-08-06 |
Apo-T B.V. |
Multispezifische bindungsmoleküle zur anzielung aberranter zellen
|
US10946104B2
(en)
|
2012-01-13 |
2021-03-16 |
Apo-Tb.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
CN110511278A
(zh)
|
2012-05-07 |
2019-11-29 |
达特茅斯大学理事会 |
抗b7-h6抗体、融合蛋白及其使用方法
|
EP3828197A1
(de)
|
2012-05-22 |
2021-06-02 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Pharmazeutische zusammensetzung, die wirtszellen enthält welche für anti-ny-eso-1 t-zellrezeptoren kodieren
|
EP3868387A1
(de)
|
2012-07-20 |
2021-08-25 |
Taiga Biotechnologies, Inc. |
Verbesserte wiederherstellung und autorenkonstitution des hämatopoietischen abteils
|
NZ704157A
(en)
|
2012-07-27 |
2018-08-31 |
Univ Illinois |
Engineering t-cell receptors
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
CA2906587C
(en)
|
2013-03-13 |
2023-02-14 |
Health Research, Inc. |
Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
|
US9937207B2
(en)
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
EP3015477B1
(de)
*
|
2013-06-26 |
2021-08-18 |
XLifeSc, Ltd. |
Hochstabiler t-zell-rezeptor und herstellungsverfahren und anwendung davon
|
CN105873945B
(zh)
|
2013-11-22 |
2020-07-17 |
伊利诺伊州大学理事会 |
工程化的高亲和力人类t细胞受体
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
ES2740930T3
(es)
*
|
2014-03-14 |
2020-02-07 |
Immunocore Ltd |
Bibliotecas de TCR
|
US10526391B2
(en)
|
2014-07-22 |
2020-01-07 |
The University Of Notre Dame Du Lac |
Molecular constructs and uses thereof
|
WO2016054086A1
(en)
*
|
2014-09-30 |
2016-04-07 |
The Regents Of The University Of California |
Codon-optimized lentiviral vector for stem cell reprogramming
|
AU2015339744B2
(en)
|
2014-10-31 |
2021-03-25 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in CART cells and uses thereof
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
GB201506642D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
EP4339287A3
(de)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modifizierte zellen und therapieverfahren
|
GB201516272D0
(en)
*
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
EP3377086B1
(de)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphozytenantigen cd5-like(cd5l)-interleukin 12b (p40)-heterodimere in der immunität
|
GB201522592D0
(en)
*
|
2015-12-22 |
2016-02-03 |
Immunocore Ltd |
T cell receptors
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
JP2019517499A
(ja)
|
2016-06-02 |
2019-06-24 |
イムノコア リミテッド |
gp100特異的TCR−抗CD3 scFv融合タンパク質の投薬レジメン
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US11453726B2
(en)
|
2016-09-15 |
2022-09-27 |
Quadrucept Bio Limited |
Multimers, tetramers and octamers
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3529359B1
(de)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumorinfiltrierende lymphozyten zur verwendung in der therapie
|
GB201617714D0
(en)
|
2016-10-19 |
2016-11-30 |
Ucl Business Plc |
T Cell receptor
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
CN108117596B
(zh)
*
|
2016-11-29 |
2023-08-29 |
香雪生命科学技术(广东)有限公司 |
针对ny-eso的高亲和力tcr
|
WO2018102678A1
(en)
|
2016-12-02 |
2018-06-07 |
Taiga Biotechnologies, Inc. |
Nanoparticle formulations
|
EP3565535A4
(de)
|
2017-01-05 |
2020-12-30 |
Fred Hutchinson Cancer Research Center |
Systeme und verfahren zur verbesserung der impfstoffwirksamkeit
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
CA3049163A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
KR20190103226A
(ko)
*
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
FI3580561T3
(fi)
|
2017-02-12 |
2023-12-12 |
Biontech Us Inc |
Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö
|
CA3056630A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
WO2018177966A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(de)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
Tumorsignatur für metastasen, zusammensetzungen von substanzen und verwendung davon
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
CN111010866A
(zh)
|
2017-05-24 |
2020-04-14 |
潘迪恩治疗公司 |
靶向免疫耐受性
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
SG11202000612TA
(en)
|
2017-08-03 |
2020-02-27 |
Taiga Biotechnologies Inc |
Methods and compositions for the treatment of melanoma
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
AU2018337142A1
(en)
|
2017-09-22 |
2020-05-07 |
Wuxi Biologics Ireland Limited. |
Novel bispecific CD3/CD19 polypeptide complexes
|
MX2020003145A
(es)
|
2017-09-22 |
2020-07-29 |
Wuxi Biologics Ireland Ltd |
Nuevos complejos de polipeptidos biespecificos.
|
WO2019069125A1
(en)
|
2017-10-06 |
2019-04-11 |
Oslo Universitetssykehus Hf |
CHIMERIC ANTIGEN RECEPTORS
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
US11820823B2
(en)
*
|
2017-10-27 |
2023-11-21 |
Kite Pharma, Inc. |
T cell receptor antigen binding molecules and methods of use thereof
|
EP3710039A4
(de)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
|
CN109837245A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
WO2019162043A1
(en)
*
|
2018-02-26 |
2019-08-29 |
Medigene Immunotherapies Gmbh |
Nyeso tcr
|
CN112119087A
(zh)
|
2018-03-14 |
2020-12-22 |
基因医疗免疫疗法有限责任公司 |
诱导型t细胞受体及其用途
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
EP3833443A1
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigenbindende mittel, die cd277 binden, und verwendungen davon
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
WO2020049496A1
(en)
|
2018-09-05 |
2020-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
T cell modification
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
CA3117539A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
AU2019404547A1
(en)
|
2018-12-21 |
2021-07-22 |
Biontech Us Inc. |
Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
US20220143087A1
(en)
|
2019-03-08 |
2022-05-12 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(de)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
BR112021026831A2
(pt)
*
|
2019-07-03 |
2022-02-22 |
Regeneron Pharma |
Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas
|
CN112300268B
(zh)
*
|
2019-08-02 |
2023-02-28 |
香雪生命科学技术(广东)有限公司 |
识别ny-eso-1抗原的高亲和力t细胞受体
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
EP4013857A1
(de)
|
2019-08-13 |
2022-06-22 |
King's College London |
Immunreaktive zellen, die mit räumlich eingeschränkter aktivität von cytokinen der il-1-superfamilie gepanzert sind
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2021163064A2
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
WO2021200857A1
(ja)
|
2020-03-30 |
2021-10-07 |
国立大学法人三重大学 |
二重特異的抗体
|
CN111690051B
(zh)
*
|
2020-06-28 |
2021-08-17 |
英威福赛生物技术有限公司 |
靶向ny-eso-1(157-165)表位的特异性t细胞受体及抗肿瘤应用
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
JP2023548045A
(ja)
|
2020-10-23 |
2023-11-15 |
アッシャー バイオセラピューティクス, インコーポレイテッド |
免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
|
AU2021426928A1
(en)
|
2021-02-09 |
2023-09-21 |
Liyang Tcr Biotherapeutics Co.Ltd |
Tcr and application thereof
|
TW202246511A
(zh)
|
2021-02-25 |
2022-12-01 |
美商萊爾免疫藥物股份有限公司 |
靶向ny-eso-1之增強免疫細胞療法
|
US20240150711A1
(en)
|
2021-03-01 |
2024-05-09 |
Dana-Farber Cancer Institute, Inc. |
Personalized redirection and reprogramming of t cells for precise targeting of tumors
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
CN117980326A
(zh)
|
2021-07-14 |
2024-05-03 |
2赛文缇生物公司 |
与来自抗体的结合结构域融合的经工程化的t细胞受体
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
WO2023077028A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Enhanced t cell therapy targeting ny-eso-1
|
WO2023077030A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230242508A1
(en)
|
2021-12-22 |
2023-08-03 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
US20230373950A1
(en)
|
2022-03-17 |
2023-11-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2023215183A1
(en)
*
|
2022-05-02 |
2023-11-09 |
Tscan Therapeutics, Inc. |
Multiplexed t cell receptor compositions, combination therapies, and uses thereof
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
CN116239700B
(zh)
*
|
2022-12-20 |
2024-06-21 |
浙江大学 |
一种肿瘤双靶向的三特异性t细胞衔接器及其应用
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
CN116284448B
(zh)
*
|
2023-02-14 |
2024-06-21 |
浙江大学 |
一种超抗原参与的三功能t细胞衔接器及其应用
|